

Review Protocols

Evidence reviews to support the update of the NICE guideline on HIV testing: increasing uptake among people who may have undiagnosed HIV – Reviews 1 & 2 of 2

FINAL

Review team

- Chris Carmona (Senior Technical Analyst)
- Diana O'Rourke (Technical Analyst)
- Stephen Robinson (Assistant Technical Analyst)

Review 1 & 2 of 2

| | Details | Additional comments |
|--------------------------|---|---|
| Review Question 1 | What are the most effective and cost-effective ways to increase the uptake of HIV testing to reduce undiagnosed HIV among people who may have been exposed to it? | Quantitative and economics. PH32&33 (Uptake of HIV testing in MSM and black Africans) reviews and economic modelling will be considered as part of the evidence base for this updated guideline. |
| Sub question 1a | What types of intervention increase awareness of the benefits of HIV testing and details of local testing services among the general public and healthcare workers? | |
| <i>RQ 1a components</i> | <ul style="list-style-type: none"> <i>i. How do you increase awareness of the need and benefits of HIV testing among people who may have undiagnosed HIV (public)?</i> <i>ii. How do you increase awareness of local HIV testing services among people who may have undiagnosed HIV (public)?</i> <i>iii. How do you increase awareness of the indicators for, and the benefits of HIV testing among those who should offer/ refer people for testing (practitioner/provider)?</i> | |
| Sub question 1b | What types of intervention increase opportunity for, and uptake of, HIV testing? | |

| | Details | Additional comments |
|--------------------------|---|---|
| RQ 1b components | <p>i. <i>What are the most effective ways of increasing offer of a HIV test to people who may have undiagnosed HIV (practitioner/provider)?</i></p> <p>ii. <i>How do you increase the uptake of HIV testing among people who may have undiagnosed HIV?</i></p> | |
| Sub question 1c | What interventions that increase awareness of the benefits of HIV testing and details of local testing services among the general public and healthcare workers; or increase opportunity for, and uptake of, HIV testing are cost effective? | |
| Review Question 2 | What factors help or hinder the uptake of HIV testing in these groups, and how can the barriers be overcome? | Qualitative |
| RQ 2 components | <p>i. <i>What factors encourage or discourage people following through from awareness of risk to taking a HIV test, and how can the barriers be overcome?</i></p> <p>ii. <i>What factors encourage or discourage people following through from offering a HIV test, or agreeing to have a HIV test, and how can the barriers be overcome?</i></p> | |
| Language | English | |
| Study design | <p>RQ 1a/b: Comparative studies including RCT, CT, before and after.</p> <p>RQ 1c: Economic studies including:</p> <ul style="list-style-type: none"> • Cost-consequences analysis; | Costing studies, 'burden of disease' studies and 'cost of illness' studies, which do not report data to inform a model will |

| | Details | Additional comments |
|------------|---|--|
| | <ul style="list-style-type: none"> • Cost-benefit analysis; • Cost-utility analysis; • Cost-effectiveness; • Cost-minimisation. <p>RQ 2: All types of qualitative primary studies will be included.</p> | <p>be excluded.</p> <p>Systematic reviews will not be included but may be used as a source of primary studies.</p> <p>Quantitative data such as surveys will not be included.</p> <p>Previous reviews done for NICE as part of the development of the PH33 and PH34 guideline will be scanned for relevant references.</p> |
| Setting | <p>Any setting where interventions to increase awareness or uptake of HIV testing will be included.</p> <p>Included countries are: Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Luxembourg, Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland, Turkey, UK, USA.</p> | <p>Western European countries, excluding those OECD countries where there are significant cultural differences – Japan, Korea, South and Central America.</p> |
| Population | <p>People who may have undiagnosed HIV infection.</p> | <p>People who have already been diagnosed with HIV are excluded, as are people who cannot provide informed consent</p> |

| | Details | Additional comments |
|--------------|--|---|
| | | to an HIV test and babies at-risk of HIV transmission vertically. |
| Intervention | <p>RQ 1a: Interventions that increase awareness of the benefits of HIV testing, and</p> <p>Interventions that increase awareness of HIV testing services</p> <p><i>Including:</i></p> <ul style="list-style-type: none"> • <i>mass-media campaigns</i> • <i>social media</i> • <i>one-to-one information provision through planned outreach activities</i> • <i>one-to-one information provision through peer education activities</i> • <i>opportunistic information provision, for example, in gatekeeper services such as NHS 111, out-of-hours GP services and helplines</i> • <i>group-based information provision through lessons, talks and group activities.</i> <p>RQ1b: Interventions that increase the uptake of a HIV test and/or</p> | |

| | Details | Additional comments |
|--|--|---------------------|
| | <p>increase the offer of HIV testing</p> <p><i>Including:</i></p> <ul style="list-style-type: none"> • <i>Changes in service delivery: opening times, appointment systems, confidentiality.</i> • <i>Increasing the number of tests offered in primary care and other settings outside sexual health services.</i> • <i>The types of test offered: self-testing, self-sampling, point-of-care and serological testing.</i> • <i>Increasing the number of settings where tests can be carried out:</i> <ul style="list-style-type: none"> ○ <i>clinical – primary care, secondary care, genito-urinary medicine, emergency and acute admissions units</i> ○ <i>custodial – prisons, initial accommodation centres and immigration removal centres</i> ○ <i>non-clinical (community) – voluntary organisations, community organisations, community pharmacies</i> ○ <i>outreach settings – bars, clubs, faith, public sex environments</i> ○ <i>medical specialities with common comorbidity for</i> | |

| | Details | Additional comments |
|------------|---|---------------------|
| | <i>example, TB services.</i> | |
| Comparator | Other intervention Normal care Before and after | |
| Outcomes | <p><u>RQ 1a: Awareness Raising</u></p> <ul style="list-style-type: none"> • the time that elapses between HIV infection and diagnosis • the number of HIV diagnoses among at risk groups • awareness of the benefits of early HIV diagnosis • awareness of what it means to be HIV-positive • awareness of HIV services, including HIV testing • the number of people at risk who intend to have an HIV test <p><u>RQ 1b: Uptake and Offer</u></p> <ul style="list-style-type: none"> • the uptake of HIV testing • the time that elapses between HIV infection and diagnosis | |

| | Details | Additional comments |
|-----------|---|---------------------|
| | <ul style="list-style-type: none"> • the number of HIV diagnoses among at risk groups • the reported history and frequency of taking HIV tests • the number of people at risk who intend to have an HIV test • the number and types of venue where HIV testing is offered <p><u>RQ 2: Barriers and Facilitators</u></p> <ul style="list-style-type: none"> • awareness of how people at risk view HIV testing and how they think the barriers to testing can be overcome • attitude towards HIV testing among people at risk and service providers (that is, whether or not there is any stigma associated with HIV test) • the barriers to HIV testing for both people at risk and service providers (for example, for those who do not speak English as a first language) • the number and types of venue where HIV testing is offered • awareness among those planning and delivering interventions of the factors that aid and hinder implementation | |
| Searching | A single systematic search of relevant databases and websites (listed below) will be carried out to identify relevant qualitative, quantitative and | |

| | Details | Additional comments |
|----------|--|--|
| | <p>cost effectiveness evidence using a combination of:</p> <p>(HIV and testing) and (services or access) and (awareness or promotion or offer or uptake) and (barriers or facilitators).</p> <p>The initial search strategy will be developed in MEDLINE (Ovid Interface) and translated use with other databases and websites. An English language filter will be placed on the search.</p> <p>Additional filters include studies on animals and removal of editorials, news items and letters.</p> | |
| Searches | <p>In accordance with Developing NICE guidelines: the manual, the following sources will be searched from 1996 to May 2015:</p> <ul style="list-style-type: none"> • Cochrane Central Register of Controlled Trials (CENTRAL) • Cochrane Database of Systematic Reviews (CDSR) • Database of Abstracts of Reviews of Effectiveness (DARE) • EconLit • Embase • EPPI-Centre (BiblioMap) • MEDLINE/MEDLINE in Process • NHS Economic Evaluation Database (NHS EED) • PsycINFO | <p>Search from 1996 as it matched introduction of effective antiretroviral therapy, and also matches start date of searches for previous reviews in PH33 & 34.</p> <p>If number of includes is low, consider searching the bibliographies of included studies for further studies (one generation only).</p> |

| | Details | Additional comments |
|--|---|---------------------|
| | <ul style="list-style-type: none"> • Social Policy and Practice <p><i>Web and hand searching</i></p> <p>In addition, the following websites will be searched manually:</p> <ul style="list-style-type: none"> • AIDSmap: http://www.aidsmap.com/ • AIDS Portal: http://www.aidsportal.org/ • AIDSinfo: https://aidsinfo.nih.gov/ • Avert: http://www.avert.org/ • Centre for Disease Control (Effective Behavioural Interventions) : http://www.cdc.gov/hiv/prevention/programs/ebis/ • Global Forum on MSM and HIV : http://www.msmsgf.org/ • Global Network of People living with HIV (GNP+): http://www.gnpplus.net/ • Google Scholar (First 100 results only after limiting by date) • National AIDS Trust: http://www.nat.org.uk/ • NLM HIV/AIDS resources: http://www.nlm.nih.gov/databases/databases_aids.html • Social Care online: http://www.scie-socialcareonline.org.uk/ • Terrence Higgins Trust (THT) http://www.tht.org.uk/ • UNAIDS : http://www.unaids.org/ • NICE Evidence (with appropriate limits) | |

| | Details | Additional comments |
|--|---|---------------------|
| Data screening | <p>All references from the database searches will be downloaded, deduplicated and screened on title and abstract against the criteria above. A randomly selected initial sample of 10% of records will be screened by two reviewers independently. The rate of agreement for this sample will be recorded, and if it is over 90% then remaining references will be screened by one reviewer only. Disagreement will be resolved through discussion.</p> <p>Where abstracts meet all the criteria, or if it is unclear from the study abstract whether it does, the full text will be retrieved. Full-text screening will be carried out by two reviewers independently on 10% and any differences resolved by discussion.</p> <p>Inter-rater agreement will be recorded.</p> <p>Reasons for exclusion at full paper will be recorded.</p> | |
| Exclusions | <ul style="list-style-type: none"> • Not English language • Dissertations and theses • Opinion pieces (e.g. letters, editorials, commentaries) • Conference abstracts • Poster presentations | |
| Data extraction and Critical Appraisal | <p>Quality assessment and data extraction for all included studies will be conducted using the tools in Developing NICE guidelines: the manual. All studies will be critically appraised and data extracted by one</p> | |

| | Details | Additional comments |
|----------------------------|---|---------------------|
| | reviewer, with all data checked in detail by a second reviewer. All extracted data will be captured in evidence tables. | |
| Data synthesis | Data will be synthesised narratively in the first instance. If sufficiently homogeneous and high-quality data are located, meta-analysis may be considered, although this is unlikely. | |
| Subgroup analysis | Where possible, the effectiveness of interventions for subgroups (for example MSM or black Africans) will be disaggregated and reported, along with any other differential effect on different subgroups. | |
| Other information/criteria | The review will report on any unintended consequences or adverse outcomes | |